查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929532

生物可分解冠狀動脈支架市場：按材料、應用、最終用戶和分銷管道分類，全球預測（2026-2032年）

Biodegradable Coronary Stents Market by Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，可生物分解冠狀動脈支架市場價值將達到 14.1 億美元，到 2026 年將成長至 15.2 億美元，到 2032 年將達到 22.4 億美元，複合年成長率為 6.79%。

主要市場統計數據
基準年 2025 14.1億美元
預計年份：2026年 15.2億美元
預測年份：2032年 22.4億美元
複合年成長率 (%) 6.79%

在新的臨床需求和技術成熟的推動下，可生物分解的冠狀動脈支架正在徹底改變以患者為中心的血管治療和手術效率。

可生物分解冠狀動脈支架代表了介入性心臟病學的一個轉折點，它將材料科學的進步與血管修復和長期血管完整性方面不斷變化的臨床需求相結合。目前的討論重點在於可吸收裝置能否在減少與永久性金屬支架相關的長期併發症的同時，實現二次介入治療和生理性血管反應。臨床醫生和醫療機構越來越關注即時手術療效和長期血管護理之間的權衡，這促使器械研發人員不斷改進支架梁設計、藥物釋放型曲線和吸收動力學。

材料創新、監管政策明朗化和以價值為導向的醫療保健模式等因素的匯聚，正在加速可生物分解支架的結構性變革。

由於技術、監管和商業性因素的共同作用，可生物分解冠狀動脈支架的市場格局正在經歷變革性變化。材料創新正從早期的聚合物概念發展到可吸收金屬和混合結構，力求在徑向強度和可預測的分解性之間取得平衡。這些技術改進，加上藥物釋放型塗層和遞送系統的迭代最佳化，正在增強臨床醫生的信心，並擴大可吸收支架的臨床應用範圍。

包括美國在 2025 年實施的關稅變化累積轉變，正在推動供應鏈重組、成本轉移和戰略採購應對措施。

2025年美國關稅政策的實施，為可生物分解冠狀動脈支架產業的企業帶來了新的商業性複雜性，促使企業即時評估其採購、生產和庫存策略。原料、成品醫療設備及相關組件的關稅調整導致到岸成本上升和利潤空間壓縮，進而影響定價策略以及與醫療系統經銷商的合約談判。供應商和製造商正透過審查其採購基礎、利用關稅諮詢服務以及探索透過貿易協定和關稅分類來降低關稅的潛在機制來應對這一挑戰。

細分市場主導的競爭格局由材料選擇、臨床適應症、醫療環境和分銷管道決定。

細分市場分析揭示了材料科學、臨床適應症、臨床環境和分銷管道如何共同影響可吸收冠狀動脈裝置的普及趨勢。材料差異化仍然至關重要：鐵基結構提供不同的分解特性和機械性能，鎂基支架在強度和吸收性之間實現了獨特的平衡，而聚合物平台（進一步細分為PDLLA和PLLA化學結構）則展現出不同的操作特性和藥物釋放型相容性。這些材料選擇直接影響手術流程、影像相容性和術後監測要求。

區域趨勢：基礎設施、監管和報銷差異導致美洲、歐洲、中東和非洲以及亞太地區的採用模式不同

區域趨勢反映了醫療基礎設施、法規結構和報銷環境的差異，對可生物分解冠狀動脈支架的推廣應用有顯著影響。在美洲，臨床醫生對介入性心臟病學技術的熟悉程度以及醫院網路結構的完善促進了技術的快速轉移，而支付方的審查和採購通訊協定則要求明確證明其臨床和經濟價值。在歐洲、中東和非洲，不同的監管體系和多樣化的報銷管道導致推廣應用的時間呈現出不均衡的局面。領先的心臟中心往往是早期採用者，隨著各國醫療體系和支付方調整其醫療政策，推廣應用的普及程度也會逐漸提高。

製造商、合約合作夥伴和經銷商的競爭格局和策略舉措會影響整個醫療保健生態系統中的技術應用和臨床協作。

競爭格局日益取決於臨床合作的深度、生產和分銷網路的靈活性以及上市後證據項目的穩健性。領先的醫療設備開發商正與學術心臟中心進行直接的臨床合作，以驗證手術效果和長期血管預後，同時拓展契約製造夥伴關係，以確保產能和組件供應的穩定性。與分銷商和綜合醫療網路的策略聯盟有助於產品在門診手術中心和多醫院系統中廣泛應用。包括醫師培訓、手術指導和售後服務臨床支援在內的專屬服務模式，有助於加速產品在高流量醫療機構的推廣應用。

在不斷變化的法規環境和貿易環境中，產業領導者可採取切實可行的策略來增強韌性、加速臨床應用並最佳化商業模式。

產業領導者應協調一系列策略行動，以增強可分解支架領域的韌性，加速產品推廣應用，並贏得臨床顧客購買傾向率。首先，應優先產生符合支付方和臨床醫生決策標準的臨床證據，重點關注真實世界結果、安全性終點以及在急性冠狀動脈症候群和穩定性心絞痛患者群體中的療效比較。其次，應制定靈活的製造地和供應商多元化計劃，以降低關稅和貿易風險，同時保持成本競爭力和準時交付的可靠性。

為了確保分析的嚴謹性，我們採用了穩健的調查方法，該方法結合了關鍵臨床相關人員的訪談、供應鏈映射和三角驗證的二手資訊分析。

本分析採用多方法調查方法，旨在確保分析的嚴謹性和實用性。研究人員對介入性心臟病專家、採購人員、監管負責人和分銷合作夥伴進行了初步的定性訪談，以獲取有關臨床表現、採購動機和營運障礙的第一手資訊。此外，研究人員還進行了供應鏈圖譜分析，追蹤組件採購、生產依賴關係和分銷管道，以識別潛在的薄弱環節和改進機會。

一份權威的綜合分析報告，重點闡述了將影響可生物分解冠狀動脈支架應用和創新軌蹟的臨床、商業和政策優先事項。

結論部分總結了核心發現，並重點闡述了其對可生物分解冠狀動脈支架生態系統中相關人員的直接影響。材料技術和器械設計的進步、日益嚴格的監管要求以及不斷演變的支付模式，共同凸顯了真實世界臨床數據和供應鏈韌性的重要性。 2025年的關稅趨勢增加了商業風險，需要採購、製造和銷售部門協同應對。器械的普及推廣不僅取決於其性能，還取決於製造商能否證明其供應的可預測性、上市後監測以及與臨床優先事項的契合度。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按材料分類的可生物分解冠狀動脈支架市場

  • 鐵
  • 鎂
  • 聚合物
    • PDLLA
    • PLLA

9. 按應用分類的可生物分解冠狀動脈支架市場

  • 急性冠狀動脈症候群
  • 穩定性心絞痛

第10章 依最終用戶分類的可生物分解冠狀動脈支架市場

  • 門診手術中心
    • 醫院所屬的門診手術中心
    • 獨立門診手術中心
  • 醫院
    • 心臟中心
    • 綜合醫院

第11章 可生物分解冠狀動脈支架市場（依通路分類）

  • 直接競標
  • 第三方經銷商

第12章 各地區可生物分解冠狀動脈支架市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 生物可分解冠狀動脈支架市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國可生物分解冠狀動脈支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國可生物分解冠狀動脈支架市場

第17章：中國可生物分解冠狀動脈支架市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amaran BIoTechnology Co., Ltd.
  • Amendia, Inc.
  • Arterial Remodeling Technologies, Inc.
  • Biomedical Structures, Inc.
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Cordis Corporation
  • Elixir Medical Corporation
  • Endologix, Inc.
  • HeartFlow, Inc.
  • Hengrui Medicine Co., Ltd.
  • Inflow Dynamics Corp.
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • OrbusNeich Medical Company
  • Reva Medical, Inc.
  • Shanghai MicroPort Medical（Group）Co., Ltd.
  • Sino Medical Sciences Technology Inc.
  • Svelte Medical Systems Ltd.
  • Terumo Corporation
  • Translumina GmbH
  • Xeltis AG
Product Code: MRR-0A38069517FD

The Biodegradable Coronary Stents Market was valued at USD 1.41 billion in 2025 and is projected to grow to USD 1.52 billion in 2026, with a CAGR of 6.79%, reaching USD 2.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.41 billion
Estimated Year [2026] USD 1.52 billion
Forecast Year [2032] USD 2.24 billion
CAGR (%) 6.79%

Emerging clinical imperatives and technological maturation reshaping biodegradable coronary stents toward patient-centric vascular healing and procedural efficiency

Biodegradable coronary stents represent an inflection point in interventional cardiology, combining advances in materials science with evolving clinical priorities for vascular restoration and long-term vessel integrity. The contemporary conversation centers on the capacity of resorbable devices to reduce late-stage complications associated with permanent metallic scaffolds while enabling secondary interventions and physiological vessel responses. Clinicians and hospital systems are increasingly weighing the trade-offs between immediate procedural efficacy and long-term vessel healing, prompting device developers to refine strut designs, drug-elution profiles, and resorption kinetics.

As regulatory pathways have become more defined for bioresorbable technologies, stakeholder attention is shifting toward clinical evidence that demonstrates durable outcomes across diverse patient cohorts and lesion types. Parallel improvements in imaging, lesion preparation techniques, and adjunctive pharmacotherapy are reinforcing the practicality of these devices in routine practice. Consequently, procurement and clinical leaders are seeking deeper insight into comparative performance, supply chain resilience, and the operational implications of adopting biodegradable stents within catheterization lab workflows. The following analysis synthesizes these dynamics to inform strategic planning across product development, commercialization, and clinical adoption programs.

Converging forces of materials innovation, regulatory clarity, and value-based care models accelerating structural shifts in the biodegradable stent landscape

The landscape for biodegradable coronary stents is undergoing transformative shifts driven by converging technological, regulatory, and commercial forces. Material innovation is advancing beyond early polymer concepts to include alternative resorbable metals and hybrid constructs that aim to balance radial strength with predictable degradation. These technical refinements, coupled with iterative improvements in drug-eluting coatings and delivery systems, are enhancing operator confidence and expanding the clinical scenarios in which resorbable scaffolds are considered viable.

Concurrently, healthcare payment models and hospital procurement strategies are placing greater emphasis on long-term patient outcomes and total cost of care. Value-based care imperatives are prompting health systems to favor devices that demonstrably reduce downstream interventions and rehospitalizations. Regulatory authorities have also clarified expectations for safety and post-market surveillance, which is enabling more efficient pathways to reimbursement and formulary inclusion. In response, manufacturers are prioritizing real-world evidence generation, partnerships with clinical centers of excellence, and lifecycle plans that address post-market data collection and iterative device improvements.

These combined shifts are creating a more competitive environment where clinical differentiation, supply reliability, and robust evidence packages determine the pace and scale of adoption. Organizations that align R&D priorities with payer requirements and clinician needs are positioned to convert technological promise into durable clinical and commercial outcomes.

Cumulative trade policy shifts including United States tariff changes in 2025 prompting supply chain realignment, cost pass-through and strategic sourcing responses

United States tariff actions enacted in 2025 have introduced a new dimension of commercial complexity for companies operating in the biodegradable coronary stents ecosystem, prompting immediate reassessments of procurement, manufacturing, and inventory strategies. Tariff adjustments on raw materials, finished medical devices, or associated components can increase landed costs and compress margins, which in turn influences pricing strategies and contractual negotiations with health systems and distributors. Suppliers and manufacturers are responding by reviewing sourcing footprints, seeking tariff advisory services, and exploring potential tariff mitigation mechanisms available under trade agreements and customs classifications.

The ripple effects extend beyond input costs. Clinical trial supply logistics, capital equipment acquisitions for manufacturing, and cross-border after-sales support are all subject to the operational frictions introduced by tariff regimes. In practice, device makers have accelerated supplier diversification, prioritized local manufacturing or assembly where feasible, and engaged more closely with distributor partners to preserve competitive tendering positions. Purchasers are likewise adapting contracting approaches to include clauses that address tariff-related cost adjustments and to evaluate total landed cost rather than purchase price alone.

Moreover, tariff changes interact with reimbursement and procurement policies, influencing how hospitals and ambulatory centers evaluate vendor bids and long-term device partnerships. Effective responses require coordinated action across regulatory affairs, supply chain, and commercial teams to ensure continuity of supply, transparency in pricing, and alignment with clinician preferences. The net result is a market environment where agility in sourcing and clarity in contractual terms are as important as clinical differentiation.

Segmentation-driven competitiveness highlighting materials selection, clinical indications, care settings and distribution pathways as determinants of adoption and procurement

Segmentation insights reveal how material science, clinical indication, care setting, and distribution pathways collectively shape adoption dynamics for resorbable coronary devices. Material-based differentiation remains foundational: iron-based constructs offer alternative degradation profiles and mechanical behaviors, magnesium-based scaffolds bring a distinct balance of strength and resorption, and polymer platforms-further delineated into PDLLA and PLLA chemistries-present different handling characteristics and drug-elution compatibility. These material choices directly influence procedural workflow, imaging compatibility, and post-procedural monitoring requirements.

Clinical applications bifurcate into patients presenting with acute coronary syndrome and those managed for stable angina, each cohort raising different evidence priorities and risk tolerances. Devices that demonstrate rapid endothelialization and predictably controlled resorption are more likely to be favored in acute settings where thrombosis risk and lesion complexity are heightened, whereas long-term vessel integrity and reduced late complications are paramount considerations in elective stable angina interventions. End-user segmentation further modulates procurement and utilization patterns: ambulatory surgical centers and hospitals display distinct purchasing cycles, inventory management capabilities, and preferences for vendor support. Within ambulatory settings, the contrasts between hospital-owned ambulatory surgical centers and independent facilities affect contracting leverage and logistics, while within hospital systems, cardiac centers and multi-specialty hospitals exhibit different decision-making processes tied to volume, specialty focus, and capital planning.

Distribution channels also play a pivotal role: direct tender relationships typically support larger institutional contracts and tighter price negotiation, whereas third-party distributors provide broader geographic reach and inventory flexibility for smaller or decentralized buyer groups. Taken together, these segmentation axes inform product positioning, clinical evidence strategies, and commercial models that manufacturers must adopt to effectively address heterogeneous customer needs.

Regional dynamics revealing divergent adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific driven by infrastructure, regulation and reimbursement

Regional dynamics exert powerful influence over the trajectory of biodegradable coronary stent adoption, reflecting differences in healthcare infrastructure, regulatory frameworks, and reimbursement environments. In the Americas, clinician familiarity with interventional cardiology innovations and the structure of hospital networks shape rapid technology transfer, but payer scrutiny and procurement protocols require clear demonstration of clinical and economic value. Across Europe, the Middle East and Africa, divergent regulatory regimes and variable reimbursement pathways create a mosaic of adoption timing, with leading cardiac centers often acting as early adopters and diffusion progressing as national health systems and payers align coverage policies.

Asia-Pacific presents a distinct landscape dominated by manufacturing ecosystems, government-led health initiatives, and rapidly expanding procedural volumes in urban centers. Local production capabilities and negotiated pricing frameworks can accelerate availability, while differences in clinical practice patterns and lesion presentations influence device selection. Transitional phrases such as moreover and consequently highlight how cross-regional partnerships, technology transfer arrangements, and regional clinical trials are shaping localized strategies. Manufacturers seeking global traction must therefore craft differentiated approaches that respect regional regulatory timelines, reimbursement considerations, and the operational realities of supply and distribution within each geography.

Competitive profiles and strategic moves by manufacturers, contract partners and distributors influencing technology diffusion and clinical partnerships across care ecosystems

Competitive dynamics are increasingly defined by the depth of clinical partnerships, the agility of manufacturing and distribution networks, and the robustness of post-market evidence programs. Leading device developers are investing in head-to-head clinical collaborations with academic cardiac centers to demonstrate procedural performance and long-term vessel outcomes, while also expanding contract manufacturing partnerships to ensure capacity and component security. Strategic alliances with distributors and integrated delivery networks enable broader reach into ambulatory surgical centers and multi-hospital systems, while dedicated service models-comprising physician training, procedural proctoring, and after-sales clinical support-bolster uptake among high-volume operators.

Companies that prioritize transparent regulatory engagement and active post-market surveillance are better positioned to address clinician concerns about durability and safety. At the same time, contract terms with health systems emphasize service-level agreements, outcome reporting commitments, and supply continuity guarantees. The competitive field is also seeing differentiated plays in adjacent value propositions such as integrated procedural kits, imaging-matched devices, and evidence-backed training curricula. Collectively, these strategic choices establish barriers to entry and create pathways for scale that prioritize clinical trust, operational reliability, and alignment with system-level performance metrics.

Actionable strategies for industry leaders to strengthen resilience, accelerate clinical adoption, and optimize commercial models amid evolving regulatory and trade environments

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture clinical mindshare in the biodegradable stent domain. First, prioritize clinical evidence generation that aligns with payer and clinician decision criteria, emphasizing real-world outcomes, safety endpoints, and comparative effectiveness across acute coronary syndrome and stable angina cohorts. Second, develop flexible manufacturing footprints and supplier diversification plans that mitigate tariff and trade risks while preserving cost competitiveness and on-time delivery reliability.

Third, tailor commercial models to the needs of distinct end users by offering differentiated support packages for hospital-owned ambulatory surgical centers, independent facilities, cardiac centers, and multi-specialty hospitals; such customization should encompass inventory solutions, clinician training, and outcome reporting tools. Fourth, refine distribution strategies to balance direct tender opportunities with selective third-party distributor partnerships that provide geographic reach without diluting service standards. Fifth, engage proactively with regional regulatory and reimbursement stakeholders to shorten time-to-formulary and to ensure that post-market surveillance commitments are integrated into lifecycle planning. Finally, embed scenario planning for trade policy shifts into corporate governance processes to enable rapid, cross-functional responses when tariff landscapes change. Together, these measures create a coherent playbook for navigating clinical, commercial, and policy complexity.

Robust research methodology integrating primary clinical stakeholder interviews, supply chain mapping and triangulated secondary intelligence to ensure analytical rigor

This analysis is grounded in a multi-method research methodology designed to ensure analytical rigor and practical relevance. Primary qualitative interviews were conducted with interventional cardiologists, procurement officers, regulatory specialists, and distribution partners to capture first-hand perspectives on clinical performance, purchasing drivers, and operational barriers. These conversations were supplemented by supply chain mapping exercises that traced component sourcing, manufacturing dependencies, and distribution pathways to identify potential points of fragility and opportunities for mitigation.

Secondary intelligence was triangulated from regulatory guidance documents, clinical trial registries, peer-reviewed clinical literature, and publicly available procurement policies to validate themes emerging from primary research. Data synthesis emphasized cross-validation, with iterative feedback loops to refine hypotheses and reconcile divergent viewpoints. Analytical frameworks included scenario analysis for trade policy impacts, segmentation-based prioritization for commercial planning, and capability gap assessments to inform recommended strategic actions. Together, these methods produced a nuanced, action-oriented body of insight tailored for device manufacturers, clinical leaders, and purchasing organizations.

Conclusive synthesis underscoring clinical, commercial and policy priorities that will determine the trajectory of biodegradable coronary stents adoption and innovation

The conclusion synthesizes the core findings and clarifies the immediate implications for stakeholders across the biodegradable coronary stents ecosystem. Technological progress in materials and device design, coupled with tighter regulatory expectations and evolving payment models, is elevating the importance of real-world evidence and supply chain resilience. Tariff developments in 2025 add a pragmatic layer of commercial risk that requires integrated responses from procurement, manufacturing, and commercial teams. Adoption trajectories will be shaped not only by device performance but also by the ability of manufacturers to demonstrate predictable supply, post-market vigilance, and alignment with institutional priorities.

Forward-looking organizations will integrate clinical, operational, and commercial strategies to convert innovation into sustained clinical adoption. This requires disciplined evidence programs, flexible sourcing and manufacturing arrangements, and commercial offerings tailored to the needs of different care settings and regional markets. Ultimately, the successful diffusion of biodegradable coronary stents will depend on how well stakeholders manage the intersection of clinical value, operational execution, and policy-driven commercial constraints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biodegradable Coronary Stents Market, by Material

  • 8.1. Iron
  • 8.2. Magnesium
  • 8.3. Polymer
    • 8.3.1. Pdlla
    • 8.3.2. Plla

9. Biodegradable Coronary Stents Market, by Application

  • 9.1. Acute Coronary Syndrome
  • 9.2. Stable Angina

10. Biodegradable Coronary Stents Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Hospital-Owned Ambulatory Surgical Centers
    • 10.1.2. Independent Ambulatory Surgical Centers
  • 10.2. Hospitals
    • 10.2.1. Cardiac Centers
    • 10.2.2. Multi-Specialty Hospitals

11. Biodegradable Coronary Stents Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Third Party Distributor

12. Biodegradable Coronary Stents Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biodegradable Coronary Stents Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biodegradable Coronary Stents Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biodegradable Coronary Stents Market

16. China Biodegradable Coronary Stents Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Amaran Biotechnology Co., Ltd.
  • 17.7. Amendia, Inc.
  • 17.8. Arterial Remodeling Technologies, Inc.
  • 17.9. Biomedical Structures, Inc.
  • 17.10. Biotronik SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cook Medical LLC
  • 17.13. Cordis Corporation
  • 17.14. Elixir Medical Corporation
  • 17.15. Endologix, Inc.
  • 17.16. HeartFlow, Inc.
  • 17.17. Hengrui Medicine Co., Ltd.
  • 17.18. Inflow Dynamics Corp.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.21. Meril Life Sciences Pvt. Ltd.
  • 17.22. OrbusNeich Medical Company
  • 17.23. Reva Medical, Inc.
  • 17.24. Shanghai MicroPort Medical (Group) Co., Ltd.
  • 17.25. Sino Medical Sciences Technology Inc.
  • 17.26. Svelte Medical Systems Ltd.
  • 17.27. Terumo Corporation
  • 17.28. Translumina GmbH
  • 17.29. Xeltis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY IRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY IRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY IRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MAGNESIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PDLLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PDLLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PDLLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PLLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PLLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PLLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITAL-OWNED AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITAL-OWNED AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITAL-OWNED AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY INDEPENDENT AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY INDEPENDENT AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY INDEPENDENT AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MULTI-SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MULTI-SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MULTI-SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 162. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)